Planet Labs PBC
PLPlanet Labs PBC's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (10 weeks in). Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Planet Labs PBC trades at $16.0, building a base and 10 weeks into that stage. That is −41.0% against its own 200-day average. It sits at 12% of a 52-week range of $11 to $51. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (14 weeks and counting).
Today the stock is building a base — week 10 of stage 1. At $16.0 it trades −41.0% versus its 200-day average and sits at 12% of its 52-week range ($11–$51).
Against the market, two honest reads. Cumulative: over the last 5.4 years the stock moved +61% while the S&P 500 moved +81% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (14 weeks and counting; last ahead the week of 2026-06-12) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price Planet Labs PBC — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Planet Labs PBC at 19.4× its FY26 revenue of $0.3 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Planet Labs PBC reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +29.2% | +17.7% | — | — |
| Stock price | +44.2% | +78.9% | +9.9% | — |
4-Factor Sector Score
No sector-relative score — Planet Labs PBC is not among the largest members shown in this industry comparison for Aerospace & Defense.
The score is a rank WITHIN a peer set: every metric is scored by percentile against the other members. Without the peer set there is no score to state, so none is invented here.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Planet Labs PBC reported $0.1 B of revenue in the Apr 26 quarter, +28.6% year on year. That is the 5th straight quarter of year-on-year growth. Over 4 years it has compounded at 24.3% a year. The last full year, FY26, came in at $0.3 B. The last four reported quarters add to $0.3 B.
FY26 revenue came in at $0.3 B (+29.2% on the year), capping 4 years at 24.3% compound. The latest quarter (Apr 26) printed $0.1 B, +28.6% year on year — the 5th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +32.1% growth against the decade's 24.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +32.0% over the last 4 quarters against +19.8%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Planet Labs PBC's operating margin is −33.3% in the Apr 26 quarter, −4.7 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −100.0% to −32.3%. The current quarter sits inside that band.
The latest quarter's operating margin is −33.3%, −4.7 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −100.0%–−32.3%.
🚨 Why the margin moved: operating margin went −4.7 pp year on year while gross margin went −1.5 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Planet Labs PBC posted a net loss of $0.1 B in the Apr 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY26 year was a loss of $0.3 B. That loss is 155.6% of the quarter's revenue.
Apr 26 profit was $−0.1 B, null year on year. On the full year, FY26 printed $−0.3 B (null).
🚨 Read this profit with care: at $−0.1 B it is larger than the whole quarter's revenue of $0.1 B — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at −33.3% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Planet Labs PBC's cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was $0.1 B of operating cash against $−0.3 B of profit. After $0.1 B of capital spending, $0.1 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of $0.1 B against reported profit of $−0.3 B, leaving free cash of $0.1 B after $0.1 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Planet Labs PBC does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Planet Labs PBC earns a ROE of −132% in FY26. Return on invested capital clears the cost of that capital by −21.8 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −80.6% net margin on 0.27× asset turns.
FY26 ROE is −132%.
🚨 Why the return is what it is — the wiring (FY26): −80.6% net margin × 0.27× asset turns × 6.05× balance-sheet leverage ≈ −131.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: −7.1% − 14.7% = a −21.8 pp spread. The 14.7% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Planet Labs PBC pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Planet Labs PBC does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Planet Labs PBC carries total debt of $0.5 B against shareholder equity of $0.4 B as of Apr 26, a debt-to-equity of 1.11. On the annual view that ratio went from 0.00 in FY22 to 2.42 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Apr 26: total debt of $0.5 B against shareholder equity of $0.4 B — a debt-to-equity of 1.11. On the annual view, debt-to-equity went from 0.00 (FY22) to 2.42 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
9.7% of Planet Labs PBC's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 9.7% of the float is sold short, and at typical trading volumes it would take about 5.7 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Planet Labs PBC: the Z-score reads 4.33. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 4.33 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 4.33.
No sector comparison is shown here — not among the largest members shown in this industry comparison.
Frequently asked questions
What is Planet Labs PBC's stock price today?
Planet Labs PBC trades at $16.0, +44.2% over the past year. The company is valued at $6.0 B. The stock sits at 12% of its 52-week range of $11–$51, −41.0% versus its 200-day average. On the tape, the price is building a base, 10 weeks in. — as of 17 September 2026.
What were Planet Labs PBC's latest quarterly results?
Planet Labs PBC reported revenue of $0.1 B and a net loss of $0.1 B for the Apr 26 quarter. Earnings per share were $−0.40. The operating margin was −33.3%, 4.7 pp lower than a year earlier. — as of 17 September 2026.
What is Planet Labs PBC's revenue?
Planet Labs PBC reported revenue of $0.1 B in the Apr 26 quarter, +28.6% year on year. For the full FY26 fiscal year, revenue was $0.3 B (+29.2%). Over the last 4 years revenue compounded at 24.3% a year. — as of 17 September 2026.
What is Planet Labs PBC's profit?
Planet Labs PBC earned $−0.1 B of net profit in the Apr 26 quarter. Full-year FY26 profit was $−0.3 B. The operating margin ran −33.3% in the latest quarter. — as of 17 September 2026.
What is Planet Labs PBC's market cap?
Planet Labs PBC's market capitalisation is $6.0 B at a stock price of $16.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
Does Planet Labs PBC pay a dividend?
No — Planet Labs PBC has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
How is Planet Labs PBC performing?
Planet Labs PBC is building a base, 10 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is Planet Labs PBC in an uptrend?
No — the price is building a base (week 10 of stage 1), trading −41.0% versus its 200-day average and at 12% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Planet Labs PBC beating the market?
Not lately — on a trailing-13-week view Planet Labs PBC is currently behind the S&P 500 (14 weeks and counting; last ahead the week of 2026-06-12), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.4 years the stock moved +61% against the S&P 500's +81% — behind the index over the full window. — as of 17 September 2026.
Will Planet Labs PBC's stock price go up?
This page publishes no price forecast for Planet Labs PBC. What it measures instead: the stock price is $16.0, the price is building a base 10 weeks in. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Planet Labs PBC?
Somewhat — short interest is 9.7% of Planet Labs PBC's tradable float, about 5.7 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Planet Labs PBC have too much debt?
It is moderate — Planet Labs PBC's debt-to-equity is 0.88. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Planet Labs PBC's capex?
Planet Labs PBC spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $0.1 B. — as of 17 September 2026.
What is Planet Labs PBC's cash flow?
Planet Labs PBC generated $0.1 B of operating cash flow in FY26 and $0.1 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $−0.3 B, so operating cash ran ahead of profit. — as of 17 September 2026.
How financially safe is Planet Labs PBC?
On the balance sheet, the Z-score reads 4.33 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Planet Labs PBC in its business cycle?
Planet Labs PBC's FY26 operating margin was −32.3%, against a 5-year band of −100.0%–−32.3%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −33.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Planet Labs PBC story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Planet Labs PBC a stock worth studying right now?
This is not investment advice. The machine read: Planet Labs PBC's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!